Home Cart 0 Sign in  
X

[ CAS No. 6683-48-3 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
3d Animation Molecule Structure of 6683-48-3
Chemical Structure| 6683-48-3
Chemical Structure| 6683-48-3
Structure of 6683-48-3 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 6683-48-3 ]

Related Doc. of [ 6683-48-3 ]

Alternatived Products of [ 6683-48-3 ]

Product Details of [ 6683-48-3 ]

CAS No. :6683-48-3 MDL No. :MFCD00833394
Formula : C15H22 Boiling Point : -
Linear Structure Formula :- InChI Key :AISXBZVAYNUAKB-UHFFFAOYSA-N
M.W : 202.34 Pubchem ID :81187
Synonyms :

Calculated chemistry of [ 6683-48-3 ]

Physicochemical Properties

Num. heavy atoms : 15
Num. arom. heavy atoms : 6
Fraction Csp3 : 0.6
Num. rotatable bonds : 0
Num. H-bond acceptors : 0.0
Num. H-bond donors : 0.0
Molar Refractivity : 67.83
TPSA : 0.0 Ų

Pharmacokinetics

GI absorption : Low
BBB permeant : No
P-gp substrate : No
CYP1A2 inhibitor : No
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : Yes
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -3.69 cm/s

Lipophilicity

Log Po/w (iLOGP) : 3.13
Log Po/w (XLOGP3) : 5.41
Log Po/w (WLOGP) : 4.34
Log Po/w (MLOGP) : 5.45
Log Po/w (SILICOS-IT) : 4.87
Consensus Log Po/w : 4.64

Druglikeness

Lipinski : 1.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 2.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -4.8
Solubility : 0.00322 mg/ml ; 0.0000159 mol/l
Class : Moderately soluble
Log S (Ali) : -5.17
Solubility : 0.00138 mg/ml ; 0.00000684 mol/l
Class : Moderately soluble
Log S (SILICOS-IT) : -5.42
Solubility : 0.00076 mg/ml ; 0.00000376 mol/l
Class : Moderately soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 0.0 alert
Leadlikeness : 2.0
Synthetic accessibility : 1.84

Safety of [ 6683-48-3 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P261-P280-P305+P351+P338 UN#:N/A
Hazard Statements:H302-H312-H315-H319-H332-H335 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 6683-48-3 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 6683-48-3 ]
  • Downstream synthetic route of [ 6683-48-3 ]

[ 6683-48-3 ] Synthesis Path-Upstream   1~20

  • 1
  • [ 6223-78-5 ]
  • [ 108-88-3 ]
  • [ 6683-48-3 ]
YieldReaction ConditionsOperation in experiment
97% for 0.416667 h; 1,1,4,4,6-pentamethyl-1,2,3,4-tetrahydronaphtalene 4:
To a solution of 2,5 dichloro-2,5 dimethylhexane 2 (10 g, 54.7 mmol) in toluene (270 Ml, 0.2 M) is slowly added aluminum trichloride (5.47 g, 41 mmol) as a solid over a 15-minute period.
The reaction is complete after 10 minutes as assayed by tlc in hexanes.
The unreacted aluminum trichloride is quenched slowly with water over 10 minutes.
Additional toluene (250 mL) is added to extract the product from the aqueous layer.
The organic layer is passed through a pad of silica gel (40 g) and eluted with toluene.
The organic layer is evaporated in vacuo to dryness to yield 1,1,4,4,6-pentamethyl-1,2,3,4-tetrahydronaphtalene 4 (11 g, 97percent yield). NMR 1.29 (s, 6H), 1.28 (s, 6H), 1.69 (s, 4H), 2.32 (s, 3H), 7.22 (d, 1H), 7.12 (s, 1H), 6.97 (dd, 1H).
97% for 0.416667 h; The synthesis of compound 8 is outlined below : To a solution of 2,5 dichloro-2, 5 [DIMETHYLHEXANE,] 2, (10 g, 54.7 [MMOL)] in toluene (270 mL 0.2 M) was slowly added aluminum trichloride (5.47 g, 41 [MMOL)] as a solid over 15 minutes time. The reaction was complete after 10 minutes as assayed by TLC in hexanes. The unreacted aluminum trichloride was quenched slowly with water over 10 minutes. Additional toluene (250 mL) was added to extract the product from the aqueous layer. The organic layer was passed through a pad of silica gel (40 [G)] and eluted with toluene. The organic layer was [EVAPORATED IN VACUO] to dryness to yield 1,1, 4,4, [6-PENTAMETHYL-1,] 2,3, 4-tetrahydronaphtalene, 4 (11g, 97percent yield). To a solution containing 1,1, 4,4, [6-PENTAMETHYL-1,] 2,3, 4-tetrahydronaphtalene, 4, (20 g, 99 [MMOL)] and methyl 5- (chloromethyl)-2-furoate, 5, (17.28 g, 99 [MMOL)] in methylene chloride (500 mL 0.2 M aluminum trichloride (16.46 g, 124 [MMOL)] was added slowly as a solid at the reflux temperature. The solution was refluxed for an additional two hours. The reaction was monitored by TLC in 10percent ethyl acetate/hexanes solution. The reaction was cooled to room temperature and the unreacted aluminum trichloride was quenched with water over 15 minutes. The crude product was extracted with methylene chloride and passed through silica gel (80 [G)] and eluted with methylene chloride. The solvent was [EVAPORATED IN VACUO] to syrup. The crude product was purified with silica gel (300g) via a plug [FILTERATION] column. Methyl [5- [ (3,] 5,5, 8, [8-PENTAMETHYL-5,] 6,7, 8-tetrahydro-2- naphthalenyl) methyl]-2-furoate, 6, was eluted with 2 percent ethyl acetate/hexanes to afford 15.4 [G] (46 percent yield). To a solution containing Methyl [5- [ (3,] 5,5, 8, 8-pentamethyl-5, 6,7, 8-tetrahydro-2-naphthalenyl) methyl]-2-furoate, 6, (15.1 g, 44 [MMOL)] in MeOH (175 mL) and water (175 mL), a solution of [NAOH] (3.53 g, 88.3 [MMOL)] in water (29 mL) was added. The reaction was stirred overnight at room temperature. After completion as judged by TLC, the solution was acidified with 1 M HCI to pH 2. The crude product was extracted in to organic layer using ethyl acetate and concentrated to afford 5- [[ (3, 5, 5, 8, 8-PENTAMETHYL-5, 6, 7, 8-TETRAHYDRO-2-NAPHTHALENYL) METHYL]-2-FUROIC] acid, 7 (15.0 g, 99 percent yield). To a solution containing [5- [ (3,] 5,5, 8, [8-PENTAMETHYL-5,] 6,7, [8-TETRAHYDRO-2-NAPHTHALENYL)] methyl]- 2-furoic acid, 7, (20.15 g, 61.77 [MMOL)] in methylene chloride (310 mL), thionyl chloride (45 mL, 617. mmol) was added. The reaction was heated under reflux for 5 hours and another batch of thionyl chloride (45 mL, 617 [MMOL)] was added. The reaction was stirred overnight at room temperature. The solution was concentrated to a syrup and filtered through a pad of silica gel [(50G),] eluted with 3percent ethyl acetate in hexanes, and [CONCENTRATED IN VACUO] to afford [5- [ (3,] 5,5, 8, [8-PENTAMETHYL-5,] 6,7, 8- tetrahydro-2-naphthalenyl) methyl]-2-furoyl chloride, 8 (17g, 80percent yield).
94% at 20℃; for 24 h; (1)
Synthesis of 5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-methylnaphthalene (b)
The synthesis process is as set forth in the chemical reaction formula below.
Into anhydrous toluene (10 mL) were added aluminum chloride (200 mg, 1.5 mmol), 2,5-dichloro-2,5-dimethylhexane (4.70 g, 25.7 mmol) followed by stirring at room temperature for 24 hours.
The reaction solution was poured into cold water and extracted by ethyl acetate.
The organic layer was washed by water, a saturated sodium hydrogen carbonate aq.
solution, and a saturated saline solution, dried over magnesium sulfate, and concentrated under reduced pressure.
The yield was 4.90 g (94percent).
1H-NMR (500 MHz, CDCl3) δ 7.20 (d, 1H, J=8.0 Hz), 7.10 (d, 1H, J=1.2 Hz), 6.95 (dd, 1H, J=6.5, 1.2 Hz), 2.29 (s, 3H), 1.67 (s, 4H), 1.28 (s, 6H), 1.26 (s, 6H).
91% With aluminum (III) chloride In dichloromethane at 20℃; for 0.0833333 h; To 2,5-dimethyl-2,5-hexanediol (10 g, 68.5 mmol) in a 500 mL flask was added reagent grade concentrated HCl (150 mL) and the solution was stirred at ambient temperature for 1 h. Water (100 mL) and CH2Cl2 (100 mL) were then added slowly and the layers were separated. The aqueous layer was washed with additional CH2Cl2 (100 mL). The combined organic layers were dried over MgSO4 and filtered thru silica gel pad. The solvent was removed to yield 10.9g (87percent) of 2,5-dichloro-2,5-dimethylhexane. The dichloride was dissolved in 150 mL Of CH2Cl2 and 9.6 mL of toluene (90 mmol) was added. AlCl3 (390 mg, 2.9 mol) was added in portions over 5 min at ambient temperature. HCl is evolved and the solution turns dark red. The reaction was placed in an ice-bath and quenched with deionized water (120 mL). Hexane (150 mL) was added and the organic layer was removed. The aqueous layer was washed with additional hexane (150 mL). The combined organic layers were washed with water (200 mL) and brine (100 mL) and dried over MgSO4. The solvent was removed in vacuo to give l,l,4,4,6-pentamethyl-l,2,3,4- tetrahydronaphthalene as a colorless oil that crystallized after storage at -2O0C.[0155] Yield: 12 g (91percent); low melting white solid; Rf = 0.7 in 100percent hexane.[0156] 1H-NMR (CDCl3, 300 MHz) δ 1.32 (s, 12H), 1.7 (s, 4H), 2.34 (s, 3H), 6.85 (dd, IH), 7.14 (d, IH), 7.22 (d, IH)[0157] 13C-NMR (CDCl3, 75 MHz) δ 21.54, 32.26, 32.32, 34.29, 34.51, 35.57, 35.63, 126.64, 126.75, 127.21, 134.93, 142.00, 144.83.
85% With aluminum (III) chloride In dichloromethane at 20℃; for 0.75 h; Reflux To a 1000 mL round-bottomed flask fitted with water condenser were added compound 1 (30.0 g, 165 mmol), toluene (35.1 mL, 330 mmol) and CH2Cl2 (150 mL). To this vigorously stirred solution was added aluminum chloride (1.92 g, 1.4 mmol) slowly in portionwise, which resulted in rapid evolution of gaseous hydrochloride acid. The reaction mixture was stirred at RT for 30min followed by additional aluminum chloride (400 mg). After the reaction mixture was stirred and heated to reflux for 15 min, it was cooled in an ice bath and quenched with 20percent HCl aqueous solution (150mL). The mixture was extracted with hexanes; the combined organic layers were washed with water and brine, dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The crude product was purified by column chromatography with hexanes to afford 2 as a white solid (28.3g, 85percent), mp 34–35°C (lit.2 34–36°C). 1H NMR (CDCl3): δ 7.40 (d, J=8.0Hz, 1H), 7.31 (s, 1H), 7.14 (d, J=8.0Hz, 1H), 2.49 (s, 3H), 1.87 (s, 4H), 1.48(s, 6H), 1.47 (s, 6H).
85% With aluminum (III) chloride In dichloromethane at 20℃; Inert atmosphere; Reflux (c) 1,1,4,4,6-Pentamethyl-1,2,3,4-tetrahydronaphthalene (2): To a 1000 mLround-bottomed flask fitted with water condenser were added compound 1(30.0 g, 165 mmol), toluene (35.1 mL, 330 mmol) and CH2Cl2 (150 mL). To thisvigorously stirred solution was added aluminum chloride (1.92 g, 1.4 mmol)slowly in portionwise, which resulted in rapid evolution of gaseoushydrochloride acid. The reaction mixture was stirred at RT for 30 minfollowed by additional aluminum chloride (400 mg). After the reactionmixture was stirred and heated to reflux for 15 min, it was cooled in an icebath and quenched with 20percent HCl aqueous solution (150 mL). The mixture wasextracted with hexanes; the combined organic layers were washed with waterand brine, dried over anhydrous Na2SO4, filtered and concentrated in vacuo.The crude product was purified by column chromatography with hexanes toafford 2 as a white solid (28.3 g, 85percent), mp 34–35 C (lit.2 34–36 C). 1H NMR(CDCl3): d 7.40 (d, J = 8.0 Hz, 1H), 7.31 (s, 1H), 7.14 (d, J = 8.0 Hz, 1H), 2.49 (s,3H), 1.87 (s, 4H), 1.48(s, 6H), 1.47 (s, 6H).
76% With aluminum (III) chloride In 1,2-dichloro-ethane for 16 h; Inert atmosphere In a 250 ml_ round-bottomed flask was weighed T-1 (1.8 g, 10 mmol). Dry DCE (20 ml_) was added followed by dry toluene (921 mg, 10 mmol, 1 equiv). Then AICI3 (133 mg, 1 mmol, 10 molpercent) was added in portions. The resulting mixture was stirred under argon for 16 h. The mixture was cooled to room temperature, and then poured on ice-water (50 ml_). The organic layer was separated and the aqueous layer was extracted with Et2

Reference: [1] Journal of Organic Chemistry, 1991, vol. 56, # 15, p. 4706 - 4713
[2] Journal of Organic Chemistry, 2001, vol. 66, # 17, p. 5772 - 5782
[3] Bioorganic and Medicinal Chemistry Letters, 2002, vol. 12, # 23, p. 3467 - 3470
[4] Patent: US2004/10033, 2004, A1, . Location in patent: Page/Page column 11
[5] Patent: WO2003/106446, 2003, A1, . Location in patent: Page 19-20
[6] Organic Letters, 2012, vol. 14, # 18, p. 4866 - 4869
[7] Bioorganic and Medicinal Chemistry, 2009, vol. 17, # 13, p. 4740 - 4746
[8] Journal of Medicinal Chemistry, 2009, vol. 52, # 19, p. 5950 - 5966
[9] Patent: US2011/172185, 2011, A1, . Location in patent: Page/Page column 8
[10] Patent: WO2011/103321, 2011, A1, . Location in patent: Page/Page column 18-19
[11] ChemMedChem, 2012, vol. 7, # 9, p. 1551 - 1566
[12] Journal of Medicinal Chemistry, 1994, vol. 37, # 18, p. 2930 - 2941
[13] Heterocyclic Communications, 2001, vol. 7, # 5, p. 455 - 460
[14] Archiv der Pharmazie, 2006, vol. 339, # 4, p. 193 - 200
[15] Patent: WO2007/22437, 2007, A2, . Location in patent: Page/Page column 52
[16] Bioorganic and Medicinal Chemistry Letters, 2014, vol. 24, # 7, p. 1742 - 1747
[17] Bioorganic and Medicinal Chemistry Letters, 2015, vol. 24, # 7, p. 1742 - 1747
[18] Journal of Medicinal Chemistry, 1988, vol. 31, # 11, p. 2182 - 2192
[19] Patent: WO2018/107289, 2018, A1, . Location in patent: Page/Page column 19
[20] Chemical and Pharmaceutical Bulletin, 1997, vol. 45, # 11, p. 1805 - 1813
[21] European Journal of Medicinal Chemistry, 2011, vol. 46, # 2, p. 468 - 479
[22] Bioorganic and Medicinal Chemistry Letters, 2010, vol. 20, # 24, p. 7385 - 7387
[23] Journal of Organic Chemistry, 1960, vol. 25, p. 708 - 711
[24] Journal of the American Chemical Society, 1940, vol. 62, p. 36,43
[25] Chemical and Pharmaceutical Bulletin, 1997, vol. 45, # 2, p. 424 - 426
[26] Bioorganic and Medicinal Chemistry Letters, 2006, vol. 16, # 9, p. 2352 - 2356
[27] Patent: US2198374, 1938, ,
  • 2
  • [ 108-88-3 ]
  • [ 6683-48-3 ]
YieldReaction ConditionsOperation in experiment
76%
Stage #1: With hydrogenchloride In water at 20℃; for 1 h;
Stage #2: With aluminum (III) chloride In dichloromethane at 20℃; for 3 h;
2,3-Dimethyl-butane-2,3-diol (20.0 g, 0.14 mol) was added portionwise to 100 mL of conc. HCl at room temperature. After stirring for 1 h, a viscous white slurry was formed. The mixture was cooled with an ice bath, 50 mL of ice-water was added, the mixture filtered and dried at reduced pressure. The residue was then dissolved in a mixture of dichloromethane (100 mL) and toluene (25.8 g, 0.28 mol). Aluminum chloride (200 mg 1.50 mmol) was added slowly and the mixture was stirred at room temperature for 3 h. The mixture was then poured to 100 mL of ice-water, extracted with dichloromethane (3*10 mL), washed with saturated sodium bicarbonate (1*10 mL) and brine (1*110 mL). After the extract was dried (MgSO4) and concentrated at reduced pressure, high-vacuum distillation of the crude afforded the title compound (Compound 6, 21.5 g, 76percent yield) as a colorless oil: 1H NMR (CDCl3, 300 MHz) δ 7.20 (d, J=7.7 Hz, 1H), 7.12 (s, 1H), 6.95 (d, J=7.7 Hz, 1H), 2.30 (s, 3H), 1.67 (s, 4H), 1.27 (s, 6H), 1.26 (s, 6H).
Reference: [1] Patent: US2005/148590, 2005, A1, . Location in patent: Page/Page column 14; 15
  • 3
  • [ 6223-78-5 ]
  • [ 6683-48-3 ]
YieldReaction ConditionsOperation in experiment
97% With aluminum (III) chloride In toluene for 0.416667 h; 1,1,4,4,6-pentamethyl-1,2,3,4-tetrahydronaphtalene 4: To a solution of 2,5 dichloro-2,5 dimethylhexane 2 (10 g, 54.7 mmol) in toluene (270 Ml, 0.2 M) is slowly added aluminum trichloride (5.47 g, 41 mmol) as a solid over a 15-minute period. The reaction is complete after 10 minutes as assayed by tlc in hexanes. The unreacted aluminum trichloride is quenched slowly with water over 10 minutes. Additional toluene (250 mL) is added to extract the product from the aqueous layer. The organic layer is passed through a pad of silica gel (40 g) and eluted with toluene. The organic layer is evaporated in vacuo to dryness to yield 1,1,4,4,6-pentamethyl-1,2,3,4-tetrahydronaphtalene4 (11g, 97percent yield). NMR 1.29 (s, 6H), 1.28 (s, 6H), 1.69 (s, 4H), 2.32 (s, 3H), 7.22 (d, 1H), 7.12 (s, 1H), 6.97 (dd, 1H).
Reference: [1] Patent: EP1105120, 2005, B1, . Location in patent: Page/Page column 13
  • 4
  • [ 6223-78-5 ]
  • [ 96042-30-7 ]
  • [ 6683-48-3 ]
Reference: [1] Patent: US8293803, 2012, B2,
  • 5
  • [ 167958-79-4 ]
  • [ 6683-48-3 ]
Reference: [1] Journal of Labelled Compounds and Radiopharmaceuticals, 1995, vol. 36, # 7, p. 701 - 712
  • 6
  • [ 110-03-2 ]
  • [ 6683-48-3 ]
Reference: [1] Journal of Organic Chemistry, 2001, vol. 66, # 17, p. 5772 - 5782
[2] Journal of Medicinal Chemistry, 1994, vol. 37, # 18, p. 2930 - 2941
[3] Journal of Medicinal Chemistry, 1988, vol. 31, # 11, p. 2182 - 2192
[4] Journal of the American Chemical Society, 1940, vol. 62, p. 36,43
[5] European Journal of Medicinal Chemistry, 2011, vol. 46, # 2, p. 468 - 479
[6] Patent: WO2011/103321, 2011, A1,
[7] Patent: US8293803, 2012, B2,
[8] ChemMedChem, 2012, vol. 7, # 9, p. 1551 - 1566
[9] Organic Letters, 2012, vol. 14, # 18, p. 4866 - 4869
[10] Bioorganic and Medicinal Chemistry Letters, 2014, vol. 24, # 7, p. 1742 - 1747
[11] Bioorganic and Medicinal Chemistry Letters, 2015, vol. 24, # 7, p. 1742 - 1747
[12] Patent: WO2018/107289, 2018, A1,
  • 7
  • [ 29020-85-7 ]
  • [ 6683-48-3 ]
Reference: [1] Journal of Labelled Compounds and Radiopharmaceuticals, 1995, vol. 36, # 7, p. 701 - 712
  • 8
  • [ 5455-94-7 ]
  • [ 6683-48-3 ]
Reference: [1] Journal of Labelled Compounds and Radiopharmaceuticals, 1995, vol. 36, # 7, p. 701 - 712
  • 9
  • [ 167958-78-3 ]
  • [ 6683-48-3 ]
Reference: [1] Journal of Labelled Compounds and Radiopharmaceuticals, 1995, vol. 36, # 7, p. 701 - 712
  • 10
  • [ 127459-66-9 ]
  • [ 6683-48-3 ]
Reference: [1] Helvetica Chimica Acta, 1989, vol. 72, p. 1537 - 1553
  • 11
  • [ 94374-39-7 ]
  • [ 6683-48-3 ]
Reference: [1] Helvetica Chimica Acta, 1989, vol. 72, p. 1537 - 1553
  • 12
  • [ 6683-48-3 ]
  • [ 92050-16-3 ]
Reference: [1] Journal of Organic Chemistry, 1960, vol. 25, p. 708 - 711
  • 13
  • [ 6683-48-3 ]
  • [ 119999-22-3 ]
Reference: [1] Journal of Organic Chemistry, 2001, vol. 66, # 17, p. 5772 - 5782
[2] Journal of Medicinal Chemistry, 1995, vol. 38, # 17, p. 3368 - 3383
[3] Journal of Medicinal Chemistry, 2013, vol. 56, # 21, p. 8432 - 8454
[4] Journal of Medicinal Chemistry, 1989, vol. 32, # 7, p. 1504 - 1517
[5] Patent: US8293803, 2012, B2,
[6] Patent: WO2013/40227, 2013, A2, . Location in patent: Page/Page column 36
  • 14
  • [ 6683-48-3 ]
  • [ 116233-17-1 ]
Reference: [1] Archiv der Pharmazie, 2006, vol. 339, # 4, p. 193 - 200
[2] Bioorganic and Medicinal Chemistry Letters, 2006, vol. 16, # 9, p. 2352 - 2356
[3] Journal of Medicinal Chemistry, 1988, vol. 31, # 11, p. 2182 - 2192
[4] Journal of Medicinal Chemistry, 1989, vol. 32, # 7, p. 1504 - 1517
[5] European Journal of Medicinal Chemistry, 2011, vol. 46, # 2, p. 468 - 479
[6] Journal of Medicinal Chemistry, 2013, vol. 56, # 5, p. 1865 - 1877
[7] Patent: WO2015/130973, 2015, A1,
[8] Journal of Medicinal Chemistry, 2016, vol. 59, # 19, p. 8924 - 8940
[9] Patent: US2018/207156, 2018, A1,
  • 15
  • [ 6683-48-3 ]
  • [ 153559-49-0 ]
Reference: [1] Journal of Organic Chemistry, 2001, vol. 66, # 17, p. 5772 - 5782
[2] Journal of Medicinal Chemistry, 1995, vol. 38, # 17, p. 3368 - 3383
[3] Journal of Labelled Compounds and Radiopharmaceuticals, 1995, vol. 36, # 7, p. 701 - 712
[4] Journal of Medicinal Chemistry, 1994, vol. 37, # 18, p. 2930 - 2941
[5] Patent: WO2011/141928, 2011, A1,
[6] Patent: WO2011/103321, 2011, A1,
  • 16
  • [ 1679-64-7 ]
  • [ 6683-48-3 ]
  • [ 1349659-51-3 ]
  • [ 153559-46-7 ]
  • [ 153559-45-6 ]
Reference: [1] Patent: WO2011/141928, 2011, A1, . Location in patent: Page/Page column 18-19
  • 17
  • [ 6683-48-3 ]
  • [ 153559-46-7 ]
Reference: [1] Journal of Organic Chemistry, 2001, vol. 66, # 17, p. 5772 - 5782
[2] Journal of Medicinal Chemistry, 1995, vol. 38, # 17, p. 3368 - 3383
[3] Journal of Medicinal Chemistry, 1994, vol. 37, # 18, p. 2930 - 2941
[4] Patent: WO2011/141928, 2011, A1,
[5] Patent: WO2011/103321, 2011, A1,
  • 18
  • [ 6683-48-3 ]
  • [ 153559-48-9 ]
Reference: [1] Journal of Organic Chemistry, 2001, vol. 66, # 17, p. 5772 - 5782
[2] Journal of Medicinal Chemistry, 1995, vol. 38, # 17, p. 3368 - 3383
[3] Journal of Labelled Compounds and Radiopharmaceuticals, 1995, vol. 36, # 7, p. 701 - 712
[4] Journal of Medicinal Chemistry, 1994, vol. 37, # 18, p. 2930 - 2941
[5] Patent: WO2011/103321, 2011, A1,
  • 19
  • [ 6683-48-3 ]
  • [ 1349659-56-8 ]
  • [ 1349659-57-9 ]
  • [ 153559-48-9 ]
Reference: [1] Patent: WO2011/141928, 2011, A1,
  • 20
  • [ 6683-48-3 ]
  • [ 169126-64-1 ]
Reference: [1] Journal of Organic Chemistry, 2001, vol. 66, # 17, p. 5772 - 5782
[2] Patent: WO2013/40227, 2013, A2,
[3] Journal of Medicinal Chemistry, 2013, vol. 56, # 21, p. 8432 - 8454
Same Skeleton Products
Historical Records

Pharmaceutical Intermediates of
[ 6683-48-3 ]

Bexarotene Related Intermediates

Chemical Structure| 110-03-2

[ 110-03-2 ]

2,5-Dimethyl-2,5-hexanediol

Chemical Structure| 1679-64-7

[ 1679-64-7 ]

4-(Methoxycarbonyl)benzoic acid

Chemical Structure| 153559-48-9

[ 153559-48-9 ]

Methyl 4-(1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)vinyl)benzoate

Chemical Structure| 119999-22-3

[ 119999-22-3 ]

6-Bromo-1,1,4,4,7-pentamethyl-1,2,3,4-tetrahydronaphthalene

Chemical Structure| 169126-64-1

[ 169126-64-1 ]

(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)boronic acid

Similar Product of
[ 6683-48-3 ]

Chemical Structure| 1391053-02-3

A1267917[ 1391053-02-3 ]

1,1,4,4,6-Pentamethyl-1,2,3,4-tetrahydronaphthalene-13C4

Reason: Stable Isotope